Three independent discounted-cash-flow-style models value TG Therapeutics, Inc. every trading day. 0 of 3 currently price TGTX above its market price.
| Free Cash Flow model | $-9,279.35 |
| Excess Profit model | $-9,104.80 |
| Residual Earnings model | $2.70 |
| Dividend Discount model | — |
| Piotroski F-Score | 5 / 9 |
| Return on invested capital | +10.7% |
| Net debt / EBITDA | 0.5× |
| Gross margin | +83.7% |
| Revenue CAGR | +504.9% |
| Cash conversion | -0.1× |
| Dividend yield | — |
| Buyback yield | +0.7% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open TGTX in StockKitty